Liabilities / Assets
52nd percentile
Higher debt load relative to assets than 52% of similar nonprofits.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.28x
Liabilities / Revenue
58th percentile
Higher debt load relative to revenue than 58% of similar nonprofits.
Net Margin
51st percentile
Higher net margin than 51% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
56th percentile
Faster asset growth than 56% of similar nonprofits.
Revenue Growth
65th percentile
Faster revenue growth than 65% of similar nonprofits.
Balance Sheet
Assets
Up$75,173,327
Up $5,407,243 (+7.8%) from 2022
Net Assets
Down$53,903,512
Down $2,023,551 (-3.6%) from 2022
Liabilities
Up$21,269,815
Up $7,430,794 (+54%) from 2022
Revenue And Expenses
Revenue
Up$40,649,086
Up $4,008,355 (+11%) from 2022
Expenses
Up$39,281,452
Up $4,436,624 (+13%) from 2022
Net Income
Down$1,367,634
Down $428,269 (-24%) from 2022
Historical Trend
Filing Detail Status
This 2023 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jan 1, 2023 to Dec 31, 2023
Mission and Program Overview
Mission
Biobridge global is organized for the exclusive purpose of supporting, as the sole member, south texas blood & tissue center (stbtc), qualtex laboratories (qualtex), gencure, and the blood & tissue center foundation (the foundation) - (see schedule o).
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2023 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $75,173,327
- Liabilities
- $21,269,815
- Net assets
- $53,903,512
- Revenue
- $40,649,086
- Expenses
- $39,281,452
- Net income
- $1,367,634